KG
Therapeutic Areas
Zymeworks Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Zanidatamab (ZW25) | HER2-positive biliary tract cancers (BTC) | Phase 2b |
| ZW171 | TA-MUC1-positive solid tumors (e.g., ovarian cancer) | Phase 1 |
| ZW191 | FRα-positive solid tumors (e.g., ovarian cancer) | Phase 1 |
| ZW220 | Advanced solid tumors | Preclinical |
Leadership Team at Zymeworks
NK
Neil Klompas
President, Chief Operating & Financial Officer
NJ
Neil Josephson
Chief Medical Officer
PM
Paul Moore
Chief Scientific Officer
CA
Christopher Astle
Senior Vice President, Chief Financial Officer
LZ
Lota Zoth
Senior Vice President, Chief Accounting Officer
AT
Ali Tehrani
Founder and former President & CEO
AP
Anthony Polverino
Board Member
KN
Kelvin Neu
Board Member